加载中
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
前收盘价
US$15.67
+US$0.31 · +2.02%
盘后
US$15.56
−US$0.11 · -0.70%
10月12日 19:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日内区间
当前US$15.67
52周区间
当前US$15.67
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
72
低估
情绪
49
多空交织
风险
37
中等风险
动量
65
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日内区间
当前US$15.67
52周区间
当前US$15.67
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8523.1万 USD | 3720.5万 USD | 206.5万 USD | 271.9万 USD | 355.5万 USD |
| 销货成本 | 1179.7万 USD | 618.8万 USD | 63.5万 USD | 68.6万 USD | 67.1万 USD |
| 毛利 | 7343.4万 USD | 3101.7万 USD | 143万 USD | 203.3万 USD | 288.4万 USD |
| 研究与开发 | 2924.6万 USD | 1387.4万 USD | 1750.2万 USD | 1858.3万 USD | 1377.8万 USD |
| 销售、一般及管理费用 | 4352.8万 USD | 2955.3万 USD | 2211万 USD | 1730.3万 USD | 1363.7万 USD |
| 营业费用 | 7277.4万 USD | 4342.7万 USD | 3961.2万 USD | 3588.6万 USD | 2741.5万 USD |
| 利息收入 | 292万 USD | 12.5万 USD | — | — | — |
| 利息支出 | — | — | 143.9万 USD | 268.5万 USD | 118.6万 USD |
| 折旧和摊销 | 34.9万 USD | 22.9万 USD | 12.8万 USD | 13.2万 USD | 14.6万 USD |
| 营业利润 | 66万 USD | −1241万 USD | −3818.2万 USD | −3385.3万 USD | −2453.1万 USD |
| 净利润 | 270万 USD | −2638.6万 USD | −4767.8万 USD | −3650.8万 USD | −2564.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年12月24日 | 1:700 | — | — |
股票拆分 | 2019年10月22日 | 1:100 | — | — |
股票拆分 | 2018年5月2日 | 1:500 | — | — |
股票拆分 | 2017年11月6日 | 1:350 | — | — |
股票拆分 | 2016年7月21日 | 1:16 | — | — |
股票拆分 | 2014年4月9日 | 1:16 | — | — |
已生效 2019年12月24日
1:700
已生效 2019年10月22日
1:100
已生效 2018年5月2日
1:500
已生效 2017年11月6日
1:350
已生效 2016年7月21日
1:16
已生效 2014年4月9日
1:16
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1463.97万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1153.52万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF502.8万0.01%954亿 USD0.05%US$233.52-0.63%
Simplify Propel Opportunities ETFSURI353.46万4.68%7606.44万 USD2.82%US$17.2565+0.23%
Vanguard Russell 2000 ETFVTWO272.23万0.01%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS189万0.01%338.69亿 USD0.31%US$78.17-0.23%
State Street SPDR S&P Health Care Equipment ETFXHE152.13万0.87%1.74亿 USD0.35%US$90.87+1.59%
iShares Micro-Cap ETFIWC139.56万0.11%13.17亿 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASState Street SPDR S&P Health Care Equipment ETFXHEiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
